I nyheteneNyheter i mediaCMC

In the news | 7th October 2026

Regulatoriske søknader til CMC: Hvorfor kontinuitet i kunnskapen er viktig

The biopharmaceutical industry has made enormous progress in digitizing scientific and manufacturing data. Yet for many organizations, the greatest risk to successful CMC regulatory submissions is no longer data availability, but knowledge continuity.

Every development program generates thousands of decisions. Why was a specification changed? What evidence supported a process adjustment? What assumptions influenced a particular development path? While the data may still exist, the scientific rationale behind those decisions is often fragmented across documents, emails, spreadsheets, presentations and individual expertise.

This challenge becomes increasingly significant as products advance toward regulatory submission. Teams change, projects are transferred between functions and sites, and key contributors move on. Without a clear record of decision lineage, organizations can find themselves reconstructing historical context that was once readily understood but was never formally captured.

A modern digital strategy must therefore do more than store data. It must preserve the relationships between data, decisions, supporting evidence and scientific reasoning to create a durable record of product knowledge throughout the development lifecycle.

In a recent SelectScience interview, industry experts explore why knowledge continuity is emerging as a strategic priority for biopharma organizations and discuss practical approaches to preserving decision lineage, supporting technology transfer and strengthening readiness for CMC regulatory submissions.

Read the full SelectScience interview.

Om forfatterne

SSimage

Ken Forman, Lead Product Manager, IDBS (left) and Mark Buswell, Director of AMB Engineering and Technology and a former Vice President at GSK (right).

Om IDBSKontakt oss

Del denne siden:

Del-knapp for LinkedIn Del-knapp for Twitter Del-knapp på Facebook knapp for deling via e-post
Svg+xml,%3Csvg%20xmlns%3D'http%3A%2F%2Fwww.w3

Slik tar du CMC-ontologien i bruk | Pistoia Alliance 2026

Bli med IDBS på Pistoia Alliance-konferansen, der Ken Forman skal se nærmere på hvordan organisasjoner kan omdanne en dokumentert CMC-ontologi til et GxP-godkjent operativt rammeverk. Finn ut hvordan man ved å knytte ontologien til eksperimentelle data kan oppnå strukturert informasjon som er klar for innlevering, noe som forbedrer datautvekslingen, overholdelsen av regelverket og effektiviteten i CMC-prosessene.

Les mer om dette
CMC

Regulatoriske søknader til CMC: Hvorfor kontinuitet i kunnskapen er viktig

Biopharma-bedrifter har investert mye i håndtering av CMC-data, men mange står fortsatt overfor en mindre synlig utfordring: å bevare kunnskapen som ligger til grunn for viktige utviklingsbeslutninger. Etter hvert som produktene går gjennom utviklingsfasene og teamene endrer seg, kan det å bevare den vitenskapelige konteksten bli like viktig som å bevare de underliggende dataene.

Les mer om dette